Sanofi (SNY) Return on Capital Employed (2018 - 2025)

Sanofi's (SNY) quarterly Return on Capital Employed came in at 6.1% in Q4 2025, down 23.7% quarter-over-quarter from 8.0% in Q2 2025.

Sanofi (SNY) Return on Capital Employed (2018 - 2025) Analysis & Trends

Sanofi has disclosed Return on Capital Employed across 2 years of filings, most recently posting 6.1% for Q4 2025.

Return on Capital Employed for Q4 2025 came in at 6.1%, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was 6.1% (changed N/A YoY), and the FY2025 annual result was 6.61%, down 56.0% from the prior year.
Return on Capital Employed came in at 6.1% for Q4 2025 at Sanofi, down from 8.0% in the prior quarter.
In the past five years, Return on Capital Employed ranged from a high of 8.0% in Q2 2025 to a low of 6.1% in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROCE (Qtr)
1	Gsk	93,699,046.73 Bn	93,699,041.77 Bn	7.76 Bn	9.49%
2	Eli Lilly	1,012.06 Bn	1,006.77 Bn	16.22 Bn	42.94%
3	Johnson & Johnson	560.67 Bn	538.62 Bn	15.96 Bn	28.18%
4	AbbVie	402.20 Bn	392.85 Bn	10.78 Bn	16.47%
5	Merck	298.59 Bn	292.94 Bn	12.09 Bn	-5.22%
6	Amgen	188.77 Bn	176.74 Bn	5.87 Bn	15.87%
7	Gilead Sciences	160.22 Bn	152.49 Bn	5.52 Bn	21.53%
8	Pfizer	148.19 Bn	135.42 Bn	-1.21 Bn	-10.20%
9	Bristol Myers Squibb	116.72 Bn	106.26 Bn	8.07 Bn	-6.84%
10	Sanofi	63.47 Mn	-6.87 Bn	9.49 Bn	-

Download Data